Skip to main content

Table 1 Clinicalf data of patients

From: Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients

Patient Diagnosis/rheumatoid factor Sex, age (years) Time of diagnosis Duration of arthritis DMARD Corticosteroids EULAR response criteria TNF staining before treatmenta
1 RA, positive Female, 55 18 years NA Methotrexate 7.5 mg/week Prednisolone 5 mg/day None 0
2 RA, positive Female, 52 6 years 2 weeks Methotrexate 17.5 mg/week Prednisolone 5 mg/day Moderate 0
3 RA, positive Female, 58 2 years 6 months Methotrexate 7.5 mg/week Prednisolone 7.5 mg/day Moderate 1
4 RA, negative Female, 57 4 years 2 weeks Methotrexate 10 mg/week None None 0
5 RA, positive Male, 56 9 years 1 month Methotrexate 7.5 mg/week Prednisolone 5 mg/day Good 1
6 RA, negative Female, 69 1 year 1 year Methotrexate 15 mg/week Prednisolon 5 mg/day Good 1
7 RA, positive Female, 66 14 years 1 week Methotrexate 10 mg/week None Moderate 0
8 RA, positive Female, 66 10 years 3 weeks Methotrexate 12.5 mg/week None Moderate 0
9 RA, positive Male, 25 7 months 3 days Methotrexate 17.5 mg/day Prednisolon 20-7.5 mg/day Moderate 0
10 RA, positive Female, 35 26 years 1 year Methotrexate 17.5 mg/day Prednisolon 7.5 mg/day Good 1
  1. DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; NA, not available; RA, rheumatoid arthritis.
  2. aThe scoring system is described in Materials and methods, Additional immunohistochemical data for patient 10.